CEUS performs well in differentiating liver lesions

Sunday, November 26 | 11:20 a.m.-11:30 a.m. | S2-SSGI01-6 | Room S405

In this session, attendees will see how contrast-enhanced ultrasound (CEUS) may be a suitable alternative to MRI in differentiating focal nodular hyperplasia (FNH) from hepatic adenoma.

In his talk, Jordan Swensson, MD, from Indiana University will discuss his team’s findings, which show that CEUS has high accuracy compared to hepatobiliary agent MRI in differentiating these liver lesions.

FNH and hepatic adenoma are liver lesions that have different risks and treatments, but overlapping imaging features make it challenging for radiologists to tell between the two. MRI with hepatobiliary agents such as gadoxetate disodium helps in this area, but Swensson and colleagues point out that this method is time-consuming and costly.

The researchers wanted to present preliminary data from a prospective clinical trial aimed at determining whether CEUS can be used in this area. They included 31 patients in their study, including 29 females and two males, with an average age of 37 years and an average body mass index (BMI) of 32.3. They also included data from 21 FNH lesions and 26 hepatic adenomas that were evaluated via MRI and then through CEUS, with two readers interpreting the images.

The team found that for all lesions, the readers showed an overall accuracy of 72.3% and 80.8%, respectively. However, it also found that the readers performed well in imaging larger lesions 2 cm or bigger with CEUS.

How much better did the readers perform in this area compared to the MR images? Attend this session to find out.